Research programme: neurodegenerative disorder therapeutics - Celgene/Evotec

Drug Profile

Research programme: neurodegenerative disorder therapeutics - Celgene/Evotec

Alternative Names: CureMN; CureMotorNeuron

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evotec AG; Harvard Stem Cell Institute
  • Developer Celgene Corporation; Evotec AG
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Parkinson's disease
  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in Germany
  • 04 Nov 2017 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA
  • 03 Aug 2017 Evotec and Fraunhofer Institute for Molecular Biology and Applied Ecology IME-ScreeningPort enter into a collaboration on induced pluripotent stem cell technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top